Ibrutinib-induced pyoderma gangrenosum.

نویسندگان

  • Martyna Sławińska
  • Wioletta Barańska-Rybak
  • Michał Sobjanek
  • Aleksandra Wilkowska
  • Andrzej Mital
  • Roman Nowicki
چکیده

710 started an oral ibrutinib therapy (3 × 140 mg/d), due to B-CLL. An ulcer biopsy revealed lymphocyte and neutrophil infiltration. No histopathologic signs of carcinoma or vasculitis were observed. After consultation with a hematologist, a tentative diagnosis of ibrutinib-induced pyoderma gangrenosum (PG) was established. In addition to ibrutinib discontinuation, daily prednisone dose was increased to 60 mg (7.3 mg/kg/d), and cyclosporin A therapy was started (150 mg twice daily; 3.3 mg/kg/d). After 10 days, a clinical improvement was observed, with pain and exudate reduction. In addition, the borders of the ulcers became flattened. The doses of corticosteroids and cyclosporin A were slowly tapered. After 6 weeks, the healing process was almost complete. PG is a noninfectious neutrophilic skin disease, with a reported incidence of 3 to 10 cases/mln/y, affecting mostly people between 20 and 50 years old. The disease usually starts as a pustule or nodule, rapidly evolving to a painful ulcer with A 64-year-old man with a history of B-cell chronic lymphocytic leukemia (B-CLL) diagnosed 8 years earlier, with concomitant diabetes, permanent atrial fibrillation, and benign prostate hyperplasia presented with multiple, painful, ulcerative skin lesions that had occurred 2 months before. The first lesion developed on the left lower limb as a pustule rapidly evolving to an enlarging, painful skin ulcer. The following lesions occurred on the right lower limb, abdominal wall, left forearm, right buttock area, and, periungually, on the fourth finger of the right hand (FIGURE 1A and 1B). Despite receiving topical and systemic (prednisone, 30 mg/d) treatment, the progression of the disease was observed. Otherwise, the patient was in good general condition, with no serological and clinical signs of infection. Owing to the presence of comorbidities, he was treated with gliclazide (30 mg/d), sotalol (40 mg/d), dabigatran (2 × 150 mg/d), and tamsulosin (0.4 mg/d). Additionally, 6 months before hospital admission, he had

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pyoderma Gangrenosum and Multiple Myeloma: A case report

A 79-year-old female came to skin clinic with an ulcer, 15×20 cm, on her left shin. The laboratory report and both the skin and bone marrow biopsies reports, showed pyoderma gangrenosum associated with multiple myeloma. The patient was referred to hematology clinic for treatment. Multiple myeloma has rarely been associated with pyoderma gangrenosum. Multiple myeloma should be investigated...

متن کامل

Introducing a Case of Pyoderma Gangrenosum in the Breast

Introduction: Pyoderma gangrenosum (PG) of the breast is a rare that present as a painful ulcer on the skin. It usually affects people in their 20s to 50s and occurs in both men and women. Typically, PG affects the legs in adults. In children, it may affect the legs, buttocks, head, and neck. Pyoderma gangrenosum is characterized by a papule, nodule, or pustule that progresses to an injured les...

متن کامل

Treatment of a refractory case of pyoderma gangrenosum with cyclosporine and mycophenolate mofetil

Pyoderma gangrenosum is a rare non infectious neutrophilic dermatosis commonly associated with underlying systemic disease. Many treatment regimens have been reported. Herein, we report a case of refractory pyoderma gangrenosum with good response to combination of cyclosporine and mycophenolate mofetil.

متن کامل

Keloid: A rare finding in Pyoderma Gangrenosum

Pyoderma gangrenosum is characterized by a chronic, non-infectious, destructive ulcer which is mostly seen on distal lower extremities, but it can be found anywhere on body. We report an 18-year old man who developed keloids after healing of his ulcers. He was a known case of chronic relapsing pyoderma gangrenosum. His previous ulcers were used to heal leaving atrophic, cigarette-paper sc...

متن کامل

Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin.

Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin J Vikse, A Rygh, K Kaisen & R Omdal To cite this article: J Vikse, A Rygh, K Kaisen & R Omdal (2016): Life-threatening rituximabinduced pyoderma gangrenosum successfully treated with intravenous immunoglobulin, Scandinavian Journal of Rheumatology, DOI: 10.1080/03009742.2016.1241298 To l...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Polskie Archiwum Medycyny Wewnetrznej

دوره 126 9  شماره 

صفحات  -

تاریخ انتشار 2016